Eli Lilly and Company (NYSE: LLY) has officially announced the launch of Lilly Employer Connect, a groundbreaking platform designed to bridge the significant access gap in U.S. obesity care. By partnering with over fifteen independent program administrators, Lilly aims to provide employers with flexible, transparent, and affordable pathways to provide chronic weight management treatments for their workforce.
Addressing the Obesity Crisis and Coverage Gap
Obesity currently affects more than 100 million adults in the United States, placing a staggering $1.7 trillion annual burden on the economy through direct medical costs and lost productivity. Despite its classification as a chronic disease, insurance coverage remains inconsistent. Currently, approximately half of all commercially insured employees in the U.S. lack covered access to essential obesity management medications.
Strategic Partnerships and Transparent Pricing
The platform’s strength lies in its diverse network of independent program administrators and pharmacy partners. These include organizations such as Mark Cuban Cost Plus Drug Company, 9amHealth, Calibrate Health, and HealthDyne, among others. This structure allows employers to tailor their benefits programs to their specific budget and workforce needs, whether they require low-cost administration or comprehensive, “wraparound” support services like virtual clinical care and behavioral coaching.
Read More: Eli Lilly Cuts Zepbound Prices for Self-Pay Patients Following White House Deal
As part of the launch, Lilly is offering Zepbound® (tirzepatide) KwikPen® to network pharmacies at a discounted price of $449 for all doses. While the final cost to the employer and employee may vary based on the specific program administrator and cost-sharing model chosen, this initiative provides a clear and predictable baseline for weight management expenses.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
Scaling Access Through Innovation
Lilly Employer Connect is designed to evolve. The company plans to continuously expand its list of program administrators, which already features notable names such as:
- 9amHealth
- Mark Cuban Cost Plus Drug Company
- GoodRx
- Calibrate Health
- eMed
- Form Health
- ReviveHealth
By decoupling obesity care from traditional, often restrictive benefit designs, Lilly is empowering employers to prioritize long-term employee health and productivity through sustainable, evidence-based medical interventions.
